Fannin Innovation Studio

Allterum Therapeutics is a biopharmaceutical company focused on developing targeted treatments for relapsed acute lymphoblastic leukemia and other cancers that express the IL-7 receptor. The company is also investigating therapies for relapsed or refractory solid tumors characterized by IL-7 receptor over-expression. Its lead product, a monoclonal antibody known as 4A10, was developed at the National Cancer Institute and is designed to specifically target and eliminate cancer cells, minimizing the side effects typically associated with conventional chemotherapy. This innovative approach aims to provide effective treatment options for pediatric patients suffering from relapsed or refractory T-cell malignancies.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.

Pulmotect, Inc. is a biopharmaceutical company based in Houston, Texas, focused on developing inhaled therapeutics to prevent and treat respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007, the company specializes in products that enhance the innate immune system, offering rapid and broad-spectrum protection against various lung infections, including bacterial pneumonia, influenza, and fungal pneumonia, as well as potential bioterror agents. One of its key products, PUL-042, is a clinical-stage inhaled therapeutic that activates the body's natural defenses within minutes, providing immediate protection against a wide range of pathogens for several days. Pulmotect aims to reduce the morbidity and mortality associated with severe respiratory diseases, thus improving outcomes for at-risk patients.

Pulmotect, Inc. is a biopharmaceutical company based in Houston, Texas, focused on developing inhaled therapeutics to prevent and treat respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007, the company specializes in products that enhance the innate immune system, offering rapid and broad-spectrum protection against various lung infections, including bacterial pneumonia, influenza, and fungal pneumonia, as well as potential bioterror agents. One of its key products, PUL-042, is a clinical-stage inhaled therapeutic that activates the body's natural defenses within minutes, providing immediate protection against a wide range of pathogens for several days. Pulmotect aims to reduce the morbidity and mortality associated with severe respiratory diseases, thus improving outcomes for at-risk patients.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the development of circulatory assist technologies. Founded in 2005, the company has created the Aortix Heart Pump, a non-surgical, catheter-deployed device designed for patients suffering from heart failure who cannot be adequately treated with medication alone. This innovative pump is implanted through a catheter inserted in the leg and is positioned between the heart and kidneys to alleviate the burden on the failing heart and improve organ perfusion. By addressing cardiorenal syndrome, Aortix aims to relieve symptoms of heart failure, particularly for patients who are diuretic resistant or in acute decompensation. The device's design allows it to be less invasive than traditional options, providing a critical solution for the significant number of adults over 40 who may face heart failure in their lifetime.